Wednesday, June 26, 2013 7:45:51 AM
By RTT News, June 26, 2013, 07:31:00 AM EDT
Vote up
(RTTNews.com) - Medivation, Inc. ( MDVN ), pursuant to its agreement with Astellas Pharma Inc.(ALPMF.PK, ALPMY.PK), Wednesday announced enrollment of the first patient in a global Phase 2 clinical trial evaluating enzalutamide as a single agent for the treatment of advanced, androgen receptor (AR)-positive, triple-negative breast cancer or TNBC. TNBC is a type of cancer which does not express any of the three most commonly targeted receptors in breast cancer; estrogen, progesterone and HER2.
Medivation added that there would be about 80 patients with AR-positive, TNBC enrolled for the trial, and each one of them will receive enzalutamide(an androgen receptor inhibitor) at a dose of 160 mg to be taken orally once daily. The primary endpoint of the trial is clinical benefit rate, defined as the proportion of patients with a best response of complete response, partial response or stable disease for 16 weeks or more than that, Medivation said.
For comments and feedback: contact editorial@rttnews.com
http://www.rttnews.com
This article appears in: News Headlines
Referenced Stocks: MDVN
Read more: http://www.nasdaq.com/article/medivation-astellas-begin-mid-stage-study-of-enzalutamide---quick-facts-20130626-00173#ixzz2XK13st4c
Recent ALPMY News
- Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev • Dow Jones News • 12/15/2023 10:53:00 PM
- Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review • Dow Jones News • 11/30/2023 11:04:00 PM
- Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints • Dow Jones News • 09/22/2023 11:02:00 AM
- Poseida Therapeutics Shares Leap on Astellas Investments • Dow Jones News • 08/07/2023 02:41:00 PM
- Poseida Therapeutics in $50 Million Investment Deal With Astellas • Dow Jones News • 08/07/2023 01:58:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM